NCT05840835 - Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions

Advanced Solid Tumor

Interventions

DRUG

IMX-110 combined with Tislelizumab

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Trial Locations (2)

RECRUITING

CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto

RECRUITING

Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo